阿尔普拉斯塔迪尔对管道通的有效性
Caitlin M Gordon1, Jason T Tan2, Roxane R Carr2
1Lower Mainland Pharmacy Services (CMG), Vancouver General Hospital, Vancouver, BC, Canada.
概括
低剂量的阿尔普拉斯塔迪尔有效地维持了在患有导管依赖性先天性心脏病 (DDCHD) 的婴儿中专有的动脉管 (PDA). 虽然发生了不良事件,但非常低的剂量显示了更少的呼吸暂停和焦灼症.
科学领域:
- 新生儿心脏病学 新生儿心脏病学
- 儿科药理学 儿科药理学
- 遗传性心脏病研究 遗传性心脏病研究
背景情况:
- 患有管道依赖性先天性心脏病 (DDCHD) 的婴儿需要专利性动脉管 (PDA) 进行全身循环.
- 阿尔普拉斯塔迪尔通常用于保持管道通透性,但最佳剂量策略需要进一步调查.
研究的目的:
- 评估低剂量阿尔普拉斯塔迪尔治疗方案在患有DDCHD的新生儿中维持PDA的有效性.
- 为了比较非常低剂量与低剂量阿尔prostadil的安全性和有效性.
- 描述与阿尔prostadil使用相关的不良药物事件和处方趋势.
主要方法:
- 对接受阿尔普拉斯塔迪尔的DDCHD新生儿进行了回顾性观察队列研究.
- 非常低剂量 (< 0.01 毫克克/公斤/分钟) 与低剂量 (≥ 0.01 毫克克/公斤/分钟) 的阿尔普拉斯塔迪尔的比较.
- 通过没有复苏事件的生存来定义有效性;使用Naranjo评分 (≥3) 评估的不良事件.
主要成果:
- 阿尔普拉斯塔迪尔在88%的患者中有效,在非常低剂量和低剂量组之间没有显著差异.
- 在51%的患者中报告了不良药物事件.
- 低剂量组与非常低剂量组相比,经历了更多的呼吸暂停和焦灼症.
结论:
- 低剂量的阿尔普拉斯塔迪尔有效维持DDCHD新生儿的PDA.
- 药物不良反应是常见的,但在使用非常低剂量的阿尔普拉斯塔迪尔时,呼吸暂停和发烧发生的频率较低.
- 这些发现支持在管理DDCHD时使用低剂量阿尔普拉斯塔迪尔治疗方案.
关键词:
阿尔普拉斯塔迪尔 (alprostadil) 是一种遗传性心脏病是一种先天性心脏病.血管管道 (ductus arteriosus) 是一个动脉管道.婴儿 婴儿 婴儿 婴儿重症监护病房是重症监护病房.儿科 儿科 儿科 儿科更多相关视频
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
3.4K
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
636
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
01:22Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K